PD-1 inhibitors in carcinomatous meningitis.

Completed Studies:

EORTC 26052 Study
Phase III trial on radiochemotherapy for glioblastoma
Study status: completed Contact person: Prof. Dr. Wolfgang Wick (National Coordinator, Heidelberg)

Patients recruited: 970 of 1150 Study status: open at three German centers: Bonn, Heidelberg, Tübingen
The EORTC 26052 study investigates whether intensifying temozolomide chemotherapy after combined radiochemotherapy with temozolomide improves the survival of patients with glioblastoma. This study, which is recruiting very rapidly, especially in the USA, is being conducted at only a few German centers. This study prospectively investigates the relevance of MGMT.